Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUR103 Calcium · 1 trial · 2 indications
Objective response rate (\[ORR\] = CR + PR) by RECISTv1.1.
| Arm | Type | Description |
|---|---|---|
| Phase 2 single agent study AUR103 calcium administered as 200 mg or 300 mg twice daily. | EXPERIMENTAL | AUR103 Calcium 200mg or 300mg will be administered twice daily |
| Name | Type | Description |
|---|---|---|
| AUR103 Calcium | DRUG | AUR103 Calcium 200mg or 300mg administered twice daily |
Inclusion Criteria: 1. Age ≥ 18 years. 2. Eastern Coorperative Oncology Group (ECOG) Performance status of 0 or 1. 3. Pathologically confirmed, well or moderately differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumour. 4. Patients should have progressed after at lea...
AUR103 Calcium is an investigational small molecule being studied for the treatment of neuroendocrine (NE) tumors, specifically advanced neuroendocrine tumors of gastrointestinal origin. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AUR103 Calcium targets CD47, a protein involved in tumor immune evasion. By targeting CD47, the drug is designed to interfere with signals that cancer cells use to avoid being destroyed by the immune system. This mechanism is being evaluated in the context of neuroendocrine tumors.
AUR103 Calcium is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced neuroendocrine tumors.
AUR103 Calcium is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received approval from regulatory agencies such as the FDA. The ongoing Phase 2 trial is designed to assess its effects in patients with advanced neuroendocrine tumors.
AUR103 Calcium is being evaluated in a Phase 2 clinical trial identified as NCT07640737, titled 'AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)'. This trial is not yet recruiting and aims to enroll 30 participants in the United States, with an age minimum of 18 years.
AUR103 Calcium is the calcium salt form of the compound AUR103. The clinical trial for this drug specifically refers to AUR103 Calcium, indicating that this formulation is the one under investigation in the Phase 2 study for advanced neuroendocrine tumors.